Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 5 versions Re-verified since Apr 24, 2018, no change to tracked fieldsv18-v22
  2. Results first posted: Aug 21, 2013
    • Primary endpoint revised
    v17
  3. Eligibility criteria expanded, about 15 words
    • Study description shortened, about 99 words
    v16
  4. Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 25 to confirmed 17
    • Primary and study completion dates changed from estimate of Aug 2013 to Nov 2012
    v15
  5. Re-verified, no change to tracked fieldsv14
Show 12 earlier versionsHide 12 earlier versions
  1. Primary and study completion dates: Aug 2012 to Aug 2013v13
  2. Re-verified, no change to tracked fieldsv12
  3. Primary and study completion dates: Aug 2011 to Aug 2012v11
  4. Re-verified, no change to tracked fieldsv10
  5. Primary and study completion dates: Aug 2010 to Aug 2011
    • Study site revised
    v9
  6. Re-verified, no change to tracked fieldsv8
  7. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v7
  8. Primary completion date: Aug 2008 to Aug 2010
    • Primary endpoint revised
    • Study completion date: Jul 2009 to Aug 2010
    • Secondary endpoints shortened, about 7 words
    v6
  9. Study description shortened, about 43 wordsv5
  10. Primary endpoints: 7 to 1v4 Show 5 more changesShow less
    • Primary completion date: Aug 2008
    • Study completion date: Jul 2009
    • Secondary endpoints expanded, about 7 words
    • Study description expanded, about 86 words
    • Study arms: 0 to 1
  11. Study Status, Oversight, Study Description, Conditions, Study Design, Eligibility, Contacts/Locationsv3
  12. Eligibility criteria expanded, about 64 words
    • Study description shortened, about 83 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical research study is to learn if dasatinib can help to control Chronic Lymphocytic Leukemia (CLL). The safety of the drug will also be studied. Optional Procedures: You will be asked to have additional blood samples drawn. These samples will be used to see how the disease is responding to the drug.
Trial Details
NCT Number NCT00364286
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Bristol-Myers Squibb
Conditions
(from sponsor)		 Leukemia, Lymphoma
Related terms Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov